CDMO, CMO, Supplier Roundup in Supporting COVID-19 Projects

By Patricia Van Arnum - DCAT Editorial Director

June 24, 2021

The latest from CDMOs/CMOs and suppliers in COVID-19 projects featuring Jubilant HollisterStier, BD, and Cryoport.

Biologics Manufacturing

Ocugen, Jubilant HollisterStier Partner for COVID-19 Vaccine Mfg
Ocugen, a Malvern, Pennsylvania-based bio/pharmaceutical company, has selected Jubilant HollisterStier, a CDMO of sterile manufacturing, as its manufacturing partner for Covaxin, Ocugen's COVID-19 vaccine candidate to prepare for potential commercial manufacturing in the US and Canadian markets.

Covaxin is a COVID-19 vaccine by Bharat Biotech, a Hyderabad, India-based bio/pharmaceutical company, which was developed in collaboration with Ocugen and the Indian Council of Medical Research at the National Institute of Virology.

Earlier this month (June 2021), Ocugen reported that it will pursue submission of a biologics license application in the US for Covaxin and will no longer pursue emergency use authorization. Ocugen recently announced that it secured exclusive rights to commercialize Covaxin in Canada and has initiated discussions with Health Canada for regulatory approval

Source: Jubilant HollisterStier, Ocugen (Jubilant partnership) and Ocugen (biologics license application)


Packaging

BD Gets Order for 2 Bn Injection Devices for COVID-19 Vaccines
Becton, Dickinson and Company (BD), a Franklin Lakes, New Jersey-based medical technology company, has received pandemic orders for needles and syringes totaling 2 billion injection devices to support global COVID-19 vaccination efforts.

This new milestone reflects commitments to governments globally, including the US, Australia, Brazil, Canada, France, Germany, India, Philippines, Saudi Arabia, South Africa, Spain and the UK, and others, as well as non-governmental organizations (NGOs) supporting vaccine deployment for developing countries. In total, BD is supporting pandemic orders for more than 40 countries, NGOs, and other partners.

BD has delivered more than 900 million injection devices globally to date (as reported on June 8, 2021), with the remaining orders to be delivered between now and the end of 2022. These devices are being shipped to governments or appointed distribution partners, where they will then be distributed to healthcare facilities based on each country's individual distribution and allocation strategy. BD continues to be in discussions with government agencies and NGOs on the need to plan ahead to ensure supply availability and place orders for delivery in late 2022 and into the future.

Source: BD


General

Cellenkos, Cryoport in Logistics Services Pact for COVID-19 Therapy
Cellenkos, a Houston, Texas-based clinical-stage bio/pharmaceutical company, has selected Cryoport, a Brentwood, Tennessee-headquartered provider of cold-chain logistics services to provide a logistics service for the shipment of Cellenkos’ COVID-19 therapy.

Under the agreement, Cryoport will deliver its Cryoport Express Shippers to Cellenkos' manufacturing facility in Houston, Texas on a weekly basis.

Source: Cryoport